Arvinas, Inc. (ARVN)
Develops drugs that destroy disease-causing proteins using the body's natural cleanup system.
$8.15-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+9.8%
The outlook
Arvinas trades near its 52-week lows with analyst consensus leaning toward Buy and an average price target about 81% above the current price. The stock sits below both its 50- and 200-day moving averages, reflecting recent downward momentum. Overall sentiment remains neutral despite the bullish analyst view.
What’s behind the score
Analyst consensusBuy — 2.3 avg of 14 analysts
Price trendBelow its 50- & 200-day averages
52-week range25% of the way from its 52-week low to high
Price targetAvg target +81% vs current price
Analyst price target
~12-month · 14 analysts$14.79average target+81.4% vs now
Now $8.15
Low $6.00High $24.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$525.8M
52-wk high
$14.51
52-wk low
$6.06
50-day avg
$8.19
200-day avg
$10.67
Trailing P/E
—